Showing results (2191-2200 of 2,271) with videos related to
Sort By:
Pageof 228
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 21, 2025
Efficacy and Safety of Lenvatinib Versus Sorafenib in Recurrent HCC After Liver Transplant: A Multi-Center Real-World StudyFederica Lo Prinzi, Federico Rossari, Antonio De Rosa, et al.Journal of Abnormal Child Psychology|July 11, 2002
Response to commentary on the multimodal treatment study of ADHD (MTA): mining the meaning of the MTAJames M Swanson, L Eugene Arnold, Benedetto Vitiello, et al.Plos One|November 19, 2013
Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trialStefano Rusconi, Paola Vitiello, Fulvio Adorni, et al.Targeted Oncology|February 12, 2024
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus DurvalumabMargherita Rimini, Eleonora Loi, Mario Domenico Rizzato, et al.Journal of Asthma and Allergy|November 17, 2022
Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE StudyGianenrico Senna, Maria Aliani, Elena Altieri, et al.Cancer Discovery|April 21, 2026
Pharmacological inhibition of PMS2 induces MMR deficiency and response to immune checkpoint blockadeJulian Blagg, Philippe Riou, Alexia Hervieu, et al.Journal of the American Academy of Child and Adolescent Psychiatry|March 12, 2002
Socioeconomic status as a moderator of ADHD treatment outcomesRicardo Rieppi, Laurence L Greenhill, Rebecca E Ford, et al.Journal of the American Academy of Child and Adolescent Psychiatry|February 24, 2001
Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatmentJ M Swanson, H C Kraemer, S P Hinshaw, et al.Journal of the American Academy of Child and Adolescent Psychiatry|August 2, 2007
Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analysesJames M Swanson, Stephen P Hinshaw, L Eugene Arnold, et al.JAMA Oncology|August 12, 2021
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE TrialErika Martinelli, Giulia Martini, Vincenzo Famiglietti, et al.Pageof 228